[1]林端瑜,唐明灯,李生栩,等.18F-FDG PET-CT在霍奇金淋巴瘤疗效评价中的临床价值[J].国际放射医学核医学杂志,2012,36(6):352-357.[doi:10.3760/cma.j.issn.1673-4114.2012.06.008]
　LIN Duan-yu,TANG Ming-deng,LI Sheng-xu,et al.A preliminary study on clinical value of 18F-FDG PET-CT in evaluation of efficacy of Hodgkin lymphoma[J].International Journal of Radiation Medicine and Nuclear Medicine,2012,36(6):352-357.[doi:10.3760/cma.j.issn.1673-4114.2012.06.008]
点击复制

18F-FDG PET-CT在霍奇金淋巴瘤疗效评价中的临床价值(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
36
期数:
2012年第6期
页码:
352-357
栏目:
PET-CT临床应用及新进展(重点专题)
出版日期:
1900-01-01

文章信息/Info

Title:
A preliminary study on clinical value of 18F-FDG PET-CT in evaluation of efficacy of Hodgkin lymphoma
作者:
林端瑜;  唐明灯;  李生栩;  刘道佳;  张杰平;  蔡志华
福建省肿瘤医院核医学科, 福州 350014
Author(s):
LIN Duan-yu;  TANG Ming-deng;  LI Sheng-xu;  LIU Dao-jia;  ZHANG Jie-ping;  CAI Zhi-hua
Department of Nuclear Medicine, Fujian Provincial Tumor Hospital, Fuzhou 350014, China
关键词:
霍奇金病; 治疗效果; 氟脱氧葡萄糖F18; 正电子发射断层显像术; 体层摄影术; X线计算机
Keywords:
Hodgkin Disease; Treatment outcome; Fluorodeoxyglucose F18; Positron emission tomography; Tomography;  X-ray computed
DOI:
10.3760/cma.j.issn.1673-4114.2012.06.008
摘要:
目的 探讨18F-FDG PET-CT在霍奇金淋巴瘤(HL)疗效评价中的临床价值。方法 回顾性分析31例HL患者化疗后的18F-FDG PET-CT图像资料,最终结果经病理和临床随访证实,并与治疗后单纯CT结果进行对比分析,采用四格表χ2进行差异的显着性检验。结果 ①31例患者共发现病灶145处,其中恶性94处、良性51处。18F-FDG PET-CT评价HL治疗效果的灵敏度、特异度、阳性预测值、阴性预测值及准确率分别为97.87%、94.12%、96.84%、96.00%和96.55%,均明显优于单纯CT检查(χ2=9.83、13.49、11.50、11.69、22.58,P均<0.05)。②31例患者经PET-CT显像后,16例(51.61%)更改治疗方案。结论 18F-FDG PET-CT是HL疗效监测的有效手段。
Abstract:
Objective To explore the clinical value of 18F-FDG PET-CT in the evaluation of efficacy of Hodgkin lymphoma(HL). Methods Thirty-one cases of post-treatment patients with HL were studied retrospectively. 18F-FDG PET-CT images after chemotherapy were compared with CT post-therapy results. The final diagnosis was based on pathology or clinical follow-ups. Results ①A total of 94 malignant lesions and 51 benign lesions were found in 31 patients in the study. The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of 18F-FDG PET-CT in the evaluation of efficacy of HL were 97.87%, 94.12%, 96.84%, 96.00% and 96.55% respectively, which were significantly superior to CT examination alone(χ2=9.83, 13.49, 11.50, 11.69, 22.58, all P<0.05). ②According to the results of PET-CT, therapeutic schedules of 16 cases(51.61%) had been changed. Conclusion 18F-FDG PET-CT is an effective method in the evaluation of efficacy of HL.

参考文献/References:

[1] Cerci JJ,Trindade E,Buccheri V,et al.Consistency of FDG-PET accuracy and cost-effectiveness in initial staging of patients with Hodgkin lymphoma across jurisdictions.Clin Lymphoma Myeloma Leuk,2011,11(4):314-320.
[2] 邓瑾,黄赖机,张秀萍,等.18F-FDG PET-CT显像在霍奇金病诊断中的应用.实用医学杂志,2010,26(8):1455-1456.
[3] Jaffe ES,Harris NL,Stein H,et al.Pathology&Genetics:tumours of haematopoietic and lymphoid tissues.Lyon:IARC Press,2001:239-244.
[4] 李国珍.临床CT诊断学.北京:巾国科学技术出版社,1994:334.
[5] 应韶旭,林果为,管一晖,等.18F-DG PET显像在恶性淋巴瘤诊断和分期中的价值.上海医学,2002,25(3):146-149.
[6] Grossbard ML.恶性淋巴瘤.周立强,李陶,译.北京:中国医药科技出版社,2010:330-352.
[7] 华逢春,管一晖,赵军,等.18F-FDG PET显像在淋巴瘤诊断和分期中的应用研究.中国医学计算机成像杂志, 2002,8(3):198-202.
[8] Spaepen K,Stroobants S,Dupont P,et al.Early restaging positron emission tomography with 18F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma.Ann Oncol,2002,13(9):1356-1363.
[9] Wong CY,Thie J,Parling-Lynch KJ,et al.Glucose-normalized standardized uptake value from 18F-FDG PET in classifying lymphomas.J Nucl Med,2005,46(10):1659-1663.
[10] 贾志云,邓候富,青春.18F-FDG PET或PET/CT显像在淋巴瘤中的应用.中国临床医学影像杂志,2008,19(2):125-127.
[11] 张敬勉,赵新明,王建方,等.18F-FDG PET-CT显像对淋巴瘤疗效评价的意义.临床误诊误治,2012,25(1):71-74.
[12] Stumpe KD,Urbinelli M,Steinert HC,et al.Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma:effectiveness and comparison with computed tomography.Eur J Nucl Med,1998,25(7):721-728.
[13] Jerusalem G,Hustinx R,Beguin Y,et al.Evaluation of therapy for lymphoma.Semin Nuel Med,2005,35(3):186-196.
[14] Gisselbrecht C,Mounier N,Andre M,et al.How to define intermediate stage in Hodgkin’s lymphoma?.Eur J Haematol Suppl,2005,(66):111-114,
[15] Hutchings M,Mikhaeel NG,Fields PA,et al.Prognostic value of interim FDG-PET after two or three cycles of chemotherapy inHodgkin lymphoma.Ann Oncol,2005,16(7):1160-1168.
[16] Hutchings M,Loft A,Hansen M,et al.FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma.Blood,2006,107(1):52-59.
[17] Zinzani PL,Tani M,Fanti S,et al.Early positron emission tomography(PET) restaging:a predictive final response in Hodgkin’s disease patients.Ann Oncol,2006,17(8):1296-1300.
[18] Gallamini A,Rigacci L,Merli F,et al.The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin’s disease.Haematologica,2006,91(4):475-481.
[19] Gallamini A,Hutchings M,Rigacci L,et al.Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma:a report from a joint Italian Danish study.J Clin Oncol,2007,25(24):3746-3752.
[20] Alici S,Bavbek SE,Kaytan E,et al.Survival outcomes in aggressive non-Hodgkin’s lymphoma according to the International Prognostic Index.J BUON,2003,8(2):121-126.
[21] 江红,李佩章,劳明.血清LDH和β2MC水平与非霍奇金淋巴瘤的预后关系.医学研究杂志,2008,37(10):91-92.
[22] 谭洁,夏学鸣,李汉冲,等.非霍奇金淋巴瘤患者血清LDH、β2MG、CD44、Npt水平的动态检测和临床相关研究.现代肿瘤医学,2004,12(5):417-420.
[23] Grewal JS,Smith LB,Winegarden JD,et al.Highly aggressive ALK-positive anaplastic large cell lymphoma with a leukemic phase and multi-organ involvement:a report of three cases and a review of the literature. Amm Hematol,2007,86(7):499-508.
[24] Federico M,Guglielmi C,Luminari S,et al.Prognostic relevance of serum β2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens.A GISL study.Haematologica,2007,92(11):1482-1488.

相似文献/References:

[1]史文杰,孟召伟,谭建.基于Deauville标准探讨18F-FDG PET/CT在霍奇金淋巴瘤复发诊断中的应用价值[J].国际放射医学核医学杂志,2016,40(2):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
　Shi Wenjie,Meng Zhaowei,Tan Jian.Value of 18F-FDG PET/CT on diagnosis of Hodgkin lymphoma recurrence using Deauville criterion[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(6):120.[doi:10.3760/cma.j.issn.1673-4114.2016.02.007]
[2]李宁,柴华,杨志,等.唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效[J].国际放射医学核医学杂志,2017,41(4):247.[doi:10.3760/cma.j.issn.1673-4114.2017.04.003]
　Li Ning,Chai Hua,Yang Zhi,et al.Clinical observation of zoledronic acid combined with 89Sr in the treatment of prostate cancer patients with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(6):247.[doi:10.3760/cma.j.issn.1673-4114.2017.04.003]

备注/Memo

备注/Memo:
收稿日期:2012-09-23。
通讯作者:林端瑜(Email:lindyl20@163.com)
更新日期/Last Update: 1900-01-01